FLT3 F691L
|
AML
|
FLT3 F691L
|
AML
|
sunitinib Sensitive: C3 – Early Trials
|
sunitinib Sensitive: C3 – Early Trials
|
FLT3 F691L
|
AML
|
FLT3 F691L
|
AML
|
sorafenib Resistant: C3 – Early Trials
|
sorafenib Resistant: C3 – Early Trials
|
FLT3 F691L
|
AML
|
FLT3 F691L
|
AML
|
quizartinib Resistant: C3 – Early Trials
|
quizartinib Resistant: C3 – Early Trials
|
FLT3 F691L
|
AML
|
FLT3 F691L
|
AML
|
pexidartinib Sensitive: D – Preclinical
|
pexidartinib Sensitive: D – Preclinical
|
FLT3 F691L
|
AML
|
FLT3 F691L
|
AML
|
TP-0903 Resistant: D – Preclinical
|
TP-0903 Resistant: D – Preclinical
|
FLT3 F691L
|
AML
|
FLT3 F691L
|
AML
|
ARO-002 Sensitive: D – Preclinical
|
ARO-002 Sensitive: D – Preclinical
|
FLT3 F691L
|
AML
|
FLT3 F691L
|
AML
|
ponatinib Sensitive: D – Preclinical
|
ponatinib Sensitive: D – Preclinical
|
FLT3 F691L
|
AML
|
FLT3 F691L
|
AML
|
PHI-101 Sensitive: D – Preclinical
|
PHI-101 Sensitive: D – Preclinical
|
FLT3 F691L
|
AML
|
FLT3 F691L
|
AML
|
JRF104 Sensitive: D – Preclinical
|
JRF104 Sensitive: D – Preclinical
|
FLT3 F691L
|
AML
|
FLT3 F691L
|
AML
|
JQ-1 Sensitive: D – Preclinical
|
JQ-1 Sensitive: D – Preclinical
|